Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.

Grisham RN, Iyer G.

Curr Treat Options Oncol. 2018 Sep 18;19(11):54. doi: 10.1007/s11864-018-0571-8. Review.

PMID:
30225651
2.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Aug 1. doi: 10.1158/1078-0432.CCR-18-0412. [Epub ahead of print]

PMID:
30068706
3.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 May 29. doi: 10.1158/1078-0432.CCR-18-0494. [Epub ahead of print]

PMID:
29844129
4.

BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.

Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, Murali R.

Histopathology. 2018 Sep;73(3):438-443. doi: 10.1111/his.13651. Epub 2018 Jun 22.

PMID:
29770477
5.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

PMID:
29757876
6.

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E.

AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.

PMID:
29489407
7.

Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].

Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V.

Gynecol Oncol Rep. 2017 Sep 29;22:118. doi: 10.1016/j.gore.2017.09.014. eCollection 2017 Nov.

8.

The roles of pathology in targeted therapy of women with gynecologic cancers.

Murali R, Grisham RN, Soslow RA.

Gynecol Oncol. 2018 Jan;148(1):213-221. doi: 10.1016/j.ygyno.2017.11.020. Epub 2017 Nov 23. Review.

PMID:
29174566
9.

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O.

Ann Oncol. 2017 Dec 1;28(12):2985-2993. doi: 10.1093/annonc/mdx525.

PMID:
28950307
10.

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation.

Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V.

Gynecol Oncol Rep. 2017 Sep 6;22:9-12. doi: 10.1016/j.gore.2017.09.001. eCollection 2017 Nov. Erratum in: Gynecol Oncol Rep. 2017 Sep 29;22:118.

11.

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.

Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.

PMID:
28709702
12.

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.

Park BY, Grisham RN, den Hollander B, Thapi D, Berman T, de Stanchina E, Zhou Q, Iyer G, Aghajanian C, Spriggs DR.

Cancer Invest. 2016 Nov 25;34(10):517-520. Epub 2016 Nov 8.

13.

Low-Grade Serous Carcinoma of the Ovary.

Grisham RN.

Oncology (Williston Park). 2016 Jul;30(7):650-2. No abstract available.

14.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

15.

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.

Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.

16.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

17.

Targeted therapies for treatment of recurrent ovarian cancer.

Grisham RN, Hyman DM, Iyer G.

Clin Adv Hematol Oncol. 2014 Mar;12(3):158-62. Review.

PMID:
24927263
18.

Management of advanced uterine leiomyosarcoma.

Hyman DM, Grisham RN, Hensley ML.

Curr Opin Oncol. 2014 Jul;26(4):422-7. doi: 10.1097/CCO.0000000000000094. Review.

PMID:
24840518
19.

Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome.

Hyman DM, Bakios L, Gualtiere G, Carr C, Grisham RN, Makker V, Sonoda Y, Aghajanian C, Jewell EL.

Gynecol Oncol. 2013 Apr;129(1):58-62. doi: 10.1016/j.ygyno.2012.12.029. Epub 2012 Dec 26.

PMID:
23274560
20.

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB.

Cancer. 2013 Feb 1;119(3):548-554. doi: 10.1002/cncr.27782. Epub 2012 Aug 28.

21.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J.

Int J Gynecol Cancer. 2012 Jun;22(5):807-11. doi: 10.1097/IGC.0b013e31824a33a2.

22.

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.

Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.

Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.

23.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

24.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C.

Invest New Drugs. 2012 Dec;30(6):2294-302. doi: 10.1007/s10637-011-9765-7. Epub 2011 Nov 10. Erratum in: Invest New Drugs. 2012 Dec;30(6):2450. Miranov, Svetlana [corrected to Mironov, Svetlana].

25.

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D.

Gynecol Oncol. 2011 Nov;123(2):196-9. doi: 10.1016/j.ygyno.2011.07.019. Epub 2011 Aug 19.

26.

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Grisham RN, Berek J, Pfisterer J, Sabbatini P.

Immunotherapy. 2011 Feb;3(2):153-62. doi: 10.2217/imt.10.100. Review.

27.

Supplemental Content

Loading ...
Support Center